Relationship between plasma concentrations and suppression of ventricular extrasystoles by flecainide acetate (R-818), a new antiarrhythmic, in patients.

To assess the relationship between plasma levels of 2,5-bis-(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)benz-amide acetate (flecainide acetate), a new antiarrhythmic, and the suppression of ventricular arrhythmias, a decreasing multiple oral dosage regimen (200 mg b.i.d.

New type sedative and soporific drug.

Trimethoxybenzoyl-glycine-diethylamide induced in dogs and cats normal sleep without preceding ataxia. A five- to ten-fold increase of the soporific dose resulted in restlessness and disorientation instead of sleep. In man, oral doses of 500 to 1500 mg caused sedation or drowsiness, or both, in half the cases.